Evidence map›Paper›PMID 39355017›Full record

ReviewFrontiers in nuclear medicine2023

Tumor microenvironment and fibroblast activation protein inhibitor (FAPI) PET: developments toward brain imaging.

Mehdi Djekidel, Rahaf Alsadi, Maya Abi Akl, Othmane Bouhali, Jim O'Doherty

Abstract readReview
In one paragraph

Review in Frontiers in nuclear medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Comparative Insights intoMolecular imaging and radionuclide therapy · 2026
    Article
  3. Article
  4. "FAPI-PET: a new chapter in oncologic molecular imaging".Annals of medicine and surgery (2012) · 2026
    Article
  5. Comparison of [European journal of nuclear medicine and molecular imaging · 2026
    Article
  6. Review
  7. Engineering the Immune Response to Biomaterials.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mehdi DjekidelDepartment of Radiology/Nuclear Medicine, Northwell Health, New York, NY, United States.
Rahaf AlsadiDivision of Arts and Science, Texas A&M University at Qatar, Doha, Qatar.
Maya Abi AklDivision of Arts and Science, Texas A&M University at Qatar, Doha, Qatar.
Othmane BouhaliDivision of Arts and Science, Texas A&M University at Qatar, Doha, Qatar.
Jim O'DohertySiemens Medical Solutions, Malvern, PA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fibroblast activation protein (FAP) is a type-II membrane bound glycoprotein specifically expressed by activated fibroblasts almost exclusively in pathological conditions including arthritis, fibrosis and cancer. FAP is overexpressed in cancer-associated fibroblasts (CAFs) located in tumor stroma, and is known to be involved in a variety of tumor-promoting activities such as angiogenesis, proliferation, resistance to chemotherapy, extracellular matrix remodeling and immunosuppression. In most cancer types, higher FAP expression is associated with worse clinical outcomes, leading to the hypothesis that FAP activity is involved in cancer development, cancer cell migration, and cancer spread. Recently, various high selectivity FAP inhibitors (FAPIs) have been developed and subsequently used for positron emission tomography (PET) imaging of different pathologies. Considering the paucity of widely available and especially mainstream reliable radioligands in brain cancer PET imaging, and the poor survival rates of patients with certain types of brain cancer such as glioblastoma, FAPI-PET represents a major development in enabling the detection of small primary or metastatic lesions in the brain due to its biological characteristics and low background accumulation. In this work, we aim to summarize the potential avenues for use of FAPI-PET, from the basic biological processes to oncologic imaging and with a main focus on brain imaging.

Indexed as

FAPI imagingneuro-oncologynuclear medicinePETradiotracer

Identifiers

PMID39355017
PMCPMC11440979

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.